Pinealon Increases Cell Viability by Suppression of Free Radical Levels and Activating Proliferative Processes
Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A. Rejuvenation Res. 2011 Oct;14(5):535–541. View source ↗
This in vitro study examined the synthetic tripeptide Pinealon (Glu-Asp-Arg) across three cell models: rat cerebellar granule cells, neutrophils, and PC12 pheochromocytoma cells. The authors reported a dose-dependent restriction of reactive oxygen species (ROS) accumulation under oxidative stress induced by both receptor-dependent and receptor-independent stimuli, accompanied by a reduction in necrotic cell death as measured by the propidium iodide assay. The protective effect was associated with a delayed time course of ERK 1/2 activation and observed modification of the cell cycle. The authors noted that ROS restriction saturated at lower concentrations while cell-cycle modulation continued at higher concentrations, and proposed that, in addition to antioxidant activity, Pinealon may interact directly with the cell genome. Independent replication of these findings outside the Khavinson research lineage has been limited in the indexed Western literature.
Scientists looked at how Pinealon behaves in three different kinds of cells in laboratory dishes: brain cells from rat cerebellum, immune cells, and a standard nerve-cell line called PC12. They stressed the cells with chemicals that produce damaging molecules called free radicals, then measured what Pinealon changed. At low doses, Pinealon reduced the buildup of free radicals and the number of cells that died. At higher doses, it also appeared to affect the cell's internal "growth cycle" — the timing program that controls when cells divide. The researchers suggested this points to two separate effects: an antioxidant action and a direct interaction with the cell's genetic machinery. This is one of the foundational laboratory studies on Pinealon, though the work was conducted by the same research group that developed the peptide.
